Stefan Glombitza
Chief Executive Officer chez FORMYCON AG
Profil
Stefan Glombitza is currently the Chief Executive Officer at Formycon AG since 2022.
Previously, he worked at Hexal AG as a Manager-Medical Affairs and at Hexal Pharmaforschung GmbH as the Head-Project Management.
Dr. Glombitza holds a doctorate degree from the University of Regensburg.
Postes actifs de Stefan Glombitza
| Sociétés | Poste | Début |
|---|---|---|
| FORMYCON AG | Chief Executive Officer | 01/07/2022 |
Anciens postes connus de Stefan Glombitza
| Sociétés | Poste | Fin |
|---|---|---|
| Hexal Pharmaforschung GmbH | Corporate Officer/Principal | - |
Hexal AG
 Hexal AG Pharmaceuticals: MajorHealth Technology H e x a l AG develops, produces, markets and distributes modern generics and medicinal products. Its areas of emphasis are cardiovascular medicinal products, pain therapy medications and gastrointestinal products. The company was founded in April 1986 and is headquartered in Holzkirchen, Germany. | Corporate Officer/Principal | - |
Formation de Stefan Glombitza
| University of Regensburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FORMYCON AG | Health Technology |
| Entreprise privées | 2 |
|---|---|
Hexal AG
Hexal AG Pharmaceuticals: MajorHealth Technology H e x a l AG develops, produces, markets and distributes modern generics and medicinal products. Its areas of emphasis are cardiovascular medicinal products, pain therapy medications and gastrointestinal products. The company was founded in April 1986 and is headquartered in Holzkirchen, Germany. | Health Technology |
| Hexal Pharmaforschung GmbH |
